research use only

Rogaratinib FGFR inhibitor

Cat.No.S8547

Rogaratinib(BAY-1163877) is a highly potent and selective small molecule inhibitor of pan‐FGFR kinase activity, which specifically inhibits FGFR1, 2, 3 and 4 with an IC50 values of 1.8 nM, <1 nM, 9.2 nM and 1.2 nM respectively. It demonstrates robust efficacy in cancers with altered FGFR mRNA expression.
Jump to

Quality Control

Batch: Purity: 96.55%
96.55

Solubility

In vitro
Batch:

DMSO : 8 mg/mL (17.14 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 466.56 Formula

C23H26N6O3S

Storage (From the date of receipt)
CAS No. 1443530-05-9 Download SDF Storage of Stock Solutions

Synonyms BAY-1163877 SMILES CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
FGFR2
<1 nM
FGFR4
1.2 nM
FGFR1
1.8 nM
FGFR3
9.2 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-31)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04595747 ACTIVE_NOT_RECRUITING
Locally Advanced Gastrointestinal Stromal Tumor; Locally Advanced Sarcoma; Metastatic Gastrointestinal Stromal Tumor; Metastatic Sarcoma; Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8; Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8; Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8; Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
National Cancer Institute (NCI)
2021-05-03 PHASE2
NCT04483505 COMPLETED
Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast
Fundacion CRIS de Investigación para Vencer el Cáncer
2020-11-25 PHASE1
NCT03762122 TERMINATED
Squamous-cell Non-small Cell Lung Cancer
Swiss Cancer Institute
2019-07-25 PHASE2
NCT03473756 COMPLETED
Urothelial Carcinoma
Bayer
2018-05-15 PHASE1
NCT04125693 COMPLETED
Cancer
Bayer
2019-10-30 PHASE2
NCT03517956 COMPLETED
Advanced or Metastatic Solid Tumor
Bayer
2018-07-25 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map